NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

ex,

Thanks for your analysis, but you are not a licensed financial professional. This one didn’t pass the bs detector either 😶 …




“This statement contains several poorly reasoned and potentially misleading points:

1. **Generalization About Reverse Splits (R/S)**: The claim that reverse stock splits (R/S) are generally viewed as a weakness is an oversimplification. While R/S can sometimes be seen negatively, as they may indicate a company's poor stock performance, they are also used as strategic tools to meet regulatory listing requirements or to attract a different class of investors. The impact of an R/S on share price and company perception varies based on context.

2. **Assumption About Company Turnaround**: The statement suggests that successful R/S occurs after a company has already turned around. This is not always true. An R/S can be part of the turnaround strategy itself.

3. **Debate Among Investors**: While it's true that opinions on R/S can vary among investors, categorizing most "longs" as against R/S without evidence is a broad generalization that doesn't account for varied investor strategies and perspectives.

4. **Claims About NASDAQ Delisting**: The statement about NWBO having been delisted from NASDAQ due to poor governance and subsequent violations is serious and requires substantiation. Without specific references or evidence, these claims remain speculative and potentially misleading.

5. **Current Compliance Allegations**: The assertion that NWBO is currently acting in ways that would violate NASDAQ rules is another serious claim that would need to be backed by concrete evidence.

Additionally, the anonymity of the statement's author and the reckless nature of the analysis further undermine its credibility:

1. **Anonymity and Accountability**: The anonymous authorship of such claims means there is a lack of accountability. Anonymity can sometimes lead to the spread of unfounded allegations, as the author is not publicly responsible for the veracity of their statements.

2. **Reckless Analysis**: The statement provides a sweeping analysis of complex financial and regulatory matters without demonstrating a thorough understanding or providing evidence. This recklessness, especially in discussing serious matters like governance violations and NASDAQ listing rules, can lead to misinformation and unfairly damage the reputation of the company in question.

The combination of anonymity and a lack of careful, evidence-based analysis makes the statement not only poorly reasoned but also potentially harmful and irresponsible.”

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html